About OncoCyte
OncoCyte is a company based in Irvine (United States) founded in 2009. OncoCyte has raised $15.35 million across 11 funding rounds from investors including SG Americas Securities and Pura Vida. The company has 49 employees as of December 31, 2024. OncoCyte has completed 2 acquisitions, including Chronix Biomedical and Insight Genetics. OncoCyte offers products and services including DetermaCNI, DetermaIO, VitaGraft Kidney, VitaGraft Liver, and GraftAssure. OncoCyte operates in a competitive market with competitors including Oncimmune, Biodesix, Mirvie, Epic Sciences and Miroculus, among others.
- Headquarter Irvine, United States
- Employees 49 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Insight Molecular Diagnostics Inc.
-
Annual Revenue
$1.88 M (USD)25.15as on Dec 31, 2024
-
Net Profit
-$60.66 M (USD)-118.36as on Dec 31, 2024
-
EBITDA
-$21.68 M (USD)-5.32as on Dec 31, 2024
-
Total Equity Funding
$15.35 M (USD)
in 11 rounds
-
Latest Funding Round
$21.74 M (USD), Post-IPO
Feb 10, 2025
-
Investors
SG Americas Securities
& 1 more
-
Employee Count
49
as on Dec 31, 2024
-
Investments & Acquisitions
Chronix Biomedical
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of OncoCyte
OncoCyte is a publicly listed company on the NASDAQ with ticker symbol IMDX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of OncoCyte
OncoCyte offers a comprehensive portfolio of products and services, including DetermaCNI, DetermaIO, VitaGraft Kidney, VitaGraft Liver, and GraftAssure.
Test to identify immune checkpoint inhibitor responders.
Detects early cancer progression after treatment.
Monitors kidney transplant health via DNA detection.
Monitors liver transplant health through DNA analysis.
Kit for assessing transplant graft health accurately.
People of OncoCyte
Unlock access to complete
Funding Insights of OncoCyte
OncoCyte has successfully raised a total of $15.35M across 11 strategic funding rounds. The most recent funding activity was a Post-IPO round of $21.74 million completed in February 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in OncoCyte
OncoCyte has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include SG Americas Securities and Pura Vida.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Investment management services are provided focusing on healthcare innovation.
|
Locked | Locked | Locked |
Investor details for OncoCyte
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OncoCyte
OncoCyte has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Chronix Biomedical and Insight Genetics.
Investment portfolio details for OncoCyte
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Molecular diagnostics company that is working to enhance the diagnosis, monitoring and treatment of cancer.
|
Locked | Locked | 2007 | Locked | |
|
Non-invasive diagnostics for cancer detection are developed through blood-based tests.
|
Locked | Locked | 1997 | Locked |
Complete acquisition details for OncoCyte
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - OncoCyte
Detailed financials for OncoCyte
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Oncocyte Comparisons
Peer comparison for OncoCyte
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of OncoCyte
OncoCyte operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Oncimmune, Biodesix, Mirvie, Epic Sciences and Miroculus, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Diagnostics and risk assessment solutions for lung cancer are developed.
|
|
| Locked | Locked | Locked |
Cancer detection diagnostics assays are developed and offered.
|
|
| Locked | Locked | Locked |
Non-invasive blood tests for prenatal fetal health predictions are offered.
|
|
| Locked | Locked | Locked |
Non-invasive tests for detecting circulating tumor cells are provided.
|
|
| Locked | Locked | Locked |
MicroRNA profiling platform is developed to detect genes in samples.
|
Detailed competitors of OncoCyte
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Oncocyte
Complete news archive for OncoCyte
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OncoCyte
OncoCyte was founded in 2009 and raised its 1st funding round 6 years after it was founded.
OncoCyte is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
Ron Andrews is the current CEO of OncoCyte.
OncoCyte is a funded company, having raised a total of $15.35M across 11 funding rounds to date.
As of Dec 31, 2024, the latest employee count at OncoCyte is 49.
Annual revenue of OncoCyte is $1.88M as on Dec 31, 2024.
Founded in 2009 and based in Irvine, United States, non-invasive diagnostic tests for cancer are developed by the company. Operations focus on analyzing blood and urine samples for biomarkers through gene expression patterns compared against a database of known cancers. Tests such as DetermaRx for non-squamous NSCLC and DetermaRx EGFR for early-stage NSCLC are offered, enabling identification of lung, breast, and bladder cancers in the biotechnology sector.
OncoCyte offers DetermaCNI, DetermaIO, VitaGraft Kidney, VitaGraft Liver, and GraftAssure.
Yes, OncoCyte is publicly traded on NASDAQ under the ticker symbol IMDX.
OncoCyte has made 2 acquisitions, including Chronix Biomedical, and Insight Genetics.
OncoCyte has 2 investors. Key investors include SG Americas Securities, and Pura Vida.
The ticker symbol of OncoCyte is IMDX on NASDAQ.